|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Pain Market Overview - Non-traditional Analgesics and Opioid Reformulations to Sustain Sector Growth
Datamonitor, Oct 2008, Pages: 128
The mature pain market has experienced a turbulent 4-year period during which the estimated seven major market sales value has fallen from an all-time high in 2004 down to $24.29 billion in 2007. However, through the growing use of non-traditional analgesics and the emergence of a number of opioid reformulations, the market is set to consolidate in a new phase of growth and prosperity.
Scope
- Analysis of 200407 prescriptions for ATC classes M1A, N1A, N1B, N2A, N2B and non-traditional analgesics split by region, class, and delivery method
- Future market assessment, including pain market forecast by region and class level through to 2017
- Brand dynamics assessment, including the current competitive landscape, marketing strategies employed, and focus on leading brands within each class
- Strategic analysis of key players in the pain market and focus of corporate strategic trends and recent licensing deals
Highlights of this title
Between 2004 and 2005, the seven major market pain market moved from a brand dominated market to one where unbranded products account for the majority of sales value. This trend strengthened over the last 2 years, with major genericization of the N2A narcotic analgesic and N2B non-narcotic analgesic classes creating this financially-driven shift.
After 2 consecutive years of declining sales, 200607 saw positive market growth of 8.7%. The pain market is forecast to continue this annual growth through to 2011 to be worth approximately $31.5 billion, driven by non-traditional analgesic brand sales for neuropathic pain and fibromyalgia.
In contrast to Pfizers focus on in-house R&D, Johnson & Johnson has turned to collaborations with specialist companies to bolster its previously lackluster pain pipeline. Additionally, smaller pain companies are increasingly collaborating to combine drug development capabilities with commercial expertise in order to bring new products to market.
Key reasons to purchase this title
- Identify and understand the commercial characteristics of the pain market across the US, Japan, 5EU, and rest of world markets
- Understand the future pain market landscape to align R&D decisions and target the indications that offer the most opportunity to your company
- Quantify the key historical company and brand dynamics that have shaped the pain market
Customers who bought this item also bought
Pain Therapeutics - Drugs, Markets and Companies
Stakeholder Opinions: Back Pain - Gain competitive edge by targeting subpopulations
The Pain Management Market Outlook To 2014: Competitive Landscape, Pipeline Analysis and Growth Opportunities
US Cancer Pain Report
Commercial Insight: CNS Market Overview - Commercial Dynamics And Outlook Of The Neurology, Pain And Psychiatry Market Sectors
The Global Pain Therapeutics Market, 3rd Edition - Market Analysis, R&D Pipelines and Competitive Landscape
The Global Pain Therapeutics Market: Market Analysis, R&D Pipelines and Competitive Landscape
Pain Management - Global Strategic Business Report
The Pain Market Outlook to 2011
Pain Management - Global Trends
Pipeline Insight: Neuropathic Pain - Emerging Drugs Fail to Capitalize in Lucrative Market
Back Pain Report 2008
|
|
|
|
